Marcum Wealth LLC Raises Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Marcum Wealth LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 13.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,363 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Marcum Wealth LLC’s holdings in AstraZeneca were worth $634,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in shares of AstraZeneca by 0.7% during the 3rd quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock worth $3,351,653,000 after purchasing an additional 358,399 shares during the last quarter. Capital International Investors raised its stake in AstraZeneca by 0.5% in the fourth quarter. Capital International Investors now owns 34,782,762 shares of the company’s stock valued at $2,342,367,000 after buying an additional 164,183 shares during the last quarter. Sanders Capital LLC raised its stake in shares of AstraZeneca by 39.0% in the fourth quarter. Sanders Capital LLC now owns 14,684,066 shares of the company’s stock worth $988,972,000 after purchasing an additional 4,122,965 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of AstraZeneca by 9.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 10,424,914 shares of the company’s stock worth $708,617,000 after purchasing an additional 889,178 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of AstraZeneca by 2.5% in the fourth quarter. Fisher Asset Management LLC now owns 9,404,023 shares of the company’s stock worth $633,361,000 after purchasing an additional 233,015 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Up 0.4 %

Shares of AZN opened at $78.88 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The stock’s 50 day moving average is $76.48 and its two-hundred day moving average is $69.82. The firm has a market cap of $244.57 billion, a P/E ratio of 38.67, a PEG ratio of 1.41 and a beta of 0.48.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, April 25th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. Analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Argus raised their price objective on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. BMO Capital Markets raised their price objective on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group began coverage on AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.